caa a22 4500 465789315 CHVBK 20180323112018.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216927 doi (NATIONALLICENCE)springer-10.1007/BF00216927 Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract [Elektronische Daten] [Alec Goldenberg, David Kelsen, James Dougherty, Gordon Magill] Summary: Iproplatin (CHIP) is a second generation cisplatin analogue which has completed its Phase I trials. We studied the efficacy and toxicity of CHIP in 36 previously untreated patients with advanced upper gastrointestinal tract adenocarcinomas (GE junction, cardia, antrum and body of the stomach). The starting dose was 275 mg/m2; course were repeated on an every four week schedule. Thirty-five patients were evaluable for response. Three partial remissions (8.5%) [95% confidence limits 2.5-15%] were seen. Toxicity was tolerable and included mild myelosuppression and mild nausea and vomiting. Although well tolerated, in patients with gastric and GE junction adenocarcinomas, CHIP chemotherapy was not more and probably slightly less, effective than the parent analogue cisplatin. Kluwer Academic Publishers, 1990 gastric cancer CHIP nationallicence Goldenberg Alec The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut Kelsen David The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut Dougherty James The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut Magill Gordon The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 71-75 0167-6997 8:1<71 1990 8 10637 https://doi.org/10.1007/BF00216927 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216927 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Goldenberg Alec The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut NATIONALLICENCE 700 1- Kelsen David The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut NATIONALLICENCE 700 1- Dougherty James The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut NATIONALLICENCE 700 1- Magill Gordon The Gastrointestinal Section, The Solid Tumor Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, 10021, New York, New York, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 71-75 0167-6997 8:1<71 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer